Induction of Murine Mucosal CCR5-Reactive Antibodies as an Anti-Human Immunodeficiency Virus Strategy

ABSTRACT The genital mucosa is the main site of initial human immunodeficiency virus type 1 (HIV-1) contact with its host. In spite of repeated sexual exposure, some individuals remain seronegative, and a small fraction of them produce immunoglobulin G (IgG) and IgA autoantibodies directed against CCR5, which is probably the cause of the CCR5-minus phenotype observed in the peripheral blood mononuclear cells of these subjects. These antibodies recognize the 89-to-102 extracellular loop of CCR5 in its native conformation. The aim of this study was to induce infection-preventing mucosal anti-CCR5 autoantibodies in individuals at high risk of HIV infection. Thus, we generated chimeric immunogens containing the relevant CCR5 peptide in the context of the capsid protein of Flock House virus, a presentation system in which it is possible to engineer conformationally constrained peptide in a highly immunogenic form. Administered in mice via the systemic or mucosal route, the immunogens elicited anti-CCR5 IgG and IgA (in sera and vaginal fluids). Analogous to exposed seronegative individuals, mice producing anti-CCR5 autoantibodies express significantly reduced levels of CCR5 on the surfaces of CD4+ cells from peripheral blood and vaginal washes. In vitro studies have shown that murine IgG and IgA (i) specifically bind human and mouse CD4+ lymphocytes and the CCR5-transfected U87 cell line, (ii) down-regulate CCR5 expression of CD4+ cells from both humans and untreated mice, (iii) inhibit Mip-1β chemotaxis of CD4+ CCR5+ lymphocytes, and (iv) neutralize HIV R5 strains. These data suggest that immune strategies aimed at generating anti-CCR5 antibodies at the level of the genital mucosa might be feasible and represent a strategy to induce mucosal HIV-protective immunity.

[1]  G. Fields,et al.  Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. , 2009, International journal of peptide and protein research.

[2]  T. Lehner,et al.  Innate and Adaptive Mucosal Immunity in Protection against HIV Infection , 2006, Advances in dental research.

[3]  Xiaohong Wang,et al.  Selection of active ScFv to G-protein-coupled receptor CCR5 using surface antigen-mimicking peptides. , 2004, Biochemistry.

[4]  L. Lopalco,et al.  CCR5-specific mucosal IgA in saliva and genital fluids of HIV-exposed seronegative subjects. , 2004, Blood.

[5]  G. Colucci,et al.  Few modifications of the Cobas Amplicor HIV Monitor 1.5 test allow reliable quantitation of HIV-1 proviral load in peripheral blood mononuclear cells. , 2004, Journal of virological methods.

[6]  Paul S. Albert,et al.  Induction of Autoantibodies to CCR5 in Macaques and Subsequent Effects upon Challenge with an R5-Tropic Simian/Human Immunodeficiency Virus , 2004, Journal of Virology.

[7]  L. Lopalco.  Humoral immunity in HIV-1 exposure: cause or effect of HIV resistance? , 2004, Current HIV research.

[8]  A. Fontanet,et al.  HIV epidemic in central african republic: High prevalence rates in both rural and urban areas , 2004, Journal of medical virology.

[9]  E. Krupitsky,et al.  The onset of HIV infection in the Leningrad region of Russia: a focus on drug and alcohol dependence , 2004, HIV medicine.

[10]  F. Kasolo,et al.  HIV/AIDS in Central Africa: Pathogenesis, Immunological and Medical Issues , 2003, International Archives of Allergy and Immunology.

[11]  P. Kozlowski,et al.  The role of mucosal immunity in prevention of HIV transmission. , 2003, Current molecular medicine.

[12]  L. Lopalco,et al.  Mucosal and systemic HIV-1-specific immunity in HIV-1-exposed but uninfected heterosexual men , 2003, AIDS.

[13]  Yufei Wang,et al.  A novel HIV-CCR5 receptor vaccine strategy in the control of mucosal SIV/HIV infection , 2003, AIDS.

[14]  A. Verani,et al.  Chemokines as natural HIV antagonists. , 2002, Current molecular medicine.

[15]  L. Lopalco,et al.  Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the α-helix of gp41 , 2002, AIDS.

[16]  R. Vaughan,et al.  Allo‐immunization elicits CCR5 antibodies, SDF‐1 chemokines, and CD8‐suppressor factors that inhibit transmission of R5 and X4 HIV‐1 in women , 2002, Clinical and experimental immunology.

[17]  P. Strange,et al.  Pathways for internalization and recycling of the chemokine receptor CCR5. , 2002, Blood.

[18]  P. Ghys,et al.  Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-seronegative African women. , 2001, The Journal of infectious diseases.

[19]  R. Kaul,et al.  Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers. , 2001, Immunology letters.

[20]  S. Kaveri,et al.  Antibodies to C-C Chemokine Receptor 5 in Normal Human IgG Block Infection of Macrophages and Lymphocytes with Primary R5-Tropic Strains of HIV-11 , 2001, The Journal of Immunology.

[21]  A. Trkola,et al.  Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140 , 2001, Journal of Virology.

[22]  L. Lopalco,et al.  CCR5-Reactive Antibodies in Seronegative Partners of HIV-Seropositive Individuals Down-Modulate Surface CCR5 In Vivo and Neutralize the Infectivity of R5 Strains of HIV-1 In Vitro1 , 2000, The Journal of Immunology.

[23]  L. Lopalco,et al.  Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons. , 1999, The Journal of infectious diseases.

[24]  L. Lopalco,et al.  Anti-CD4 antibodies in exposed seronegative adults and in newborns of HIV type 1-seropositive mothers: a follow-up study. , 1999, AIDS research and human retroviruses.

[25]  William C. Olson,et al.  Differential Inhibition of Human Immunodeficiency Virus Type 1 Fusion, gp120 Binding, and CC-Chemokine Activity by Monoclonal Antibodies to CCR5 , 1999, Journal of Virology.

[26]  M. Dierich,et al.  Neutralization of HIV type 1 by alloimmune sera derived from polytransfused patients. , 1999, AIDS research and human retroviruses.

[27]  E. Buratti,et al.  The neutralizing antibody response against a conserved region of human immunodeficiency virus type 1 gp41 (amino acid residues 731-752) is uniquely directed against a conformational epitope. , 1998, The Journal of general virology.

[28]  J. Phair,et al.  A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation , 1998, Nature Medicine.

[29]  M. Clerici,et al.  HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals , 1997, Nature Medicine.

[30]  A. Trkola,et al.  Co-receptors for HIV-1 entry. , 1997, Current opinion in immunology.

[31]  Partho Ghosh,et al.  Structure of the complex between human T-cell receptor, viral peptide and HLA-A2 , 1996, Nature.

[32]  Richard A Koup,et al.  Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection , 1996, Cell.

[33]  P. Bates.  Chemokine Receptors and HIV-1: An Attractive Pair? , 1996, Cell.

[34]  Kees,et al.  Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. , 1994, The Journal of clinical investigation.

[35]  F. Baralle,et al.  Immunoreactivity of chimeric proteins carrying the HIV‐1 epitope IGPGRAF Correlation between predicted conformation and antigenicity , 1994, FEBS letters.

[36]  John E. Johnson,et al.  Ordered duplex RNA controls capsid architecture in an icosahedral animal virus , 1993, Nature.

[37]  D. King,et al.  A cleavage method which minimizes side reactions following Fmoc solid phase peptide synthesis. , 1990, International journal of peptide and protein research.

[38]  J. Darlix,et al.  The chaperoning and assistance roles of the HIV-1 nucleocapsid protein in proviral DNA synthesis and maintenance. , 2004, The international journal of biochemistry & cell biology.

[39]  M. Newell.  Antenatal and perinatal strategies to prevent mother-to-child transmission of HIV infection. , 2003, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[40]  E. Buratti,et al.  V3 loop core region serotyping of HIV-1 infected patients using the FHV epitope presenting system. , 1997, Journal of virological methods.

[41]  E. Buratti,et al.  Conformational display of two neutralizing epitopes of HIV-1 gp41 on the Flock House virus capsid protein. , 1996, Journal of immunological methods.

[42]  F. Baralle,et al.  A new epitope presenting system displays a HIV-1 V3 loop sequence and induces neutralizing antibodies. , 1995, Vaccine.